Independent of fast or slow progressing diseases accuracy and reliability of diagnostic values are of great importance. In this edition of our DiaLog we would like to keep you informed about our work on HbA1c and Procalcitonin in this regard. We are constantly working on the question of standardization of our HbA1c net FS assay to improve the comparability between different technologies. For our recently introduced Procalcitonin FS test, I would like to draw your attention to the latest peer-reviewed publication by Prof. Cristol from the institute CHU (Centre hospitalier universitaire) in Montpellier, France. The study confirmed that DiaSys' new Procalcitonin FS assay is a reliable alternative to competitor assays.

As a new and fast-progressing disease, COVID-19 has become the focus of attention around the world in recent months. Over the past months, DiaSys has provided information on DiaSys products for monitoring patients with COVID-19 infection. Additional important information will follow in the coming weeks, including an extraordinary highlight since DiaSys is currently developing a new assay to measure antibodies in the course of a COVID-19 infection.

Furthermore, I would like to raise your interest in our newly introduced online training programs for the DiaSys system solutions including special product-related information. The online training includes our newest family member, the respons®940 and the lately launched Procalcitonin FS assay. The training will continue to evolve in future, so please stay tuned and participate in our program.

As already mentioned in the last issue of DiaLog in February 2020, DiaSys continues to work as before, successfully adapting to the new conditions in the context of COVID-19 and will further continue to go this way.

We hope that all of you are safe and healthy in these turbulent times; we wish you all the best and especially health.

Sincerely yours,
Dr. Jan Gorka